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INTRODUCTION
Understanding of RNA biology has deeply expanded during last 
years. Since new RNA structures with different functions were 
discovered, it is now possible to conceive it as a structure with 
multiples signaling functions. These advances allowed using 
it as an experimental tool or even in the therapeutic field of 
clinical medicine. In fact, ribozymes, antisense RNA, aptamers, 
micro RNA (miRNA) or small interfering RNA (siRNA) are all 
used to decrease protein expression and characterize its function 
in gain or loss strategy or ultimately test its efficacy as novel 
therapy.
Almost 20 years ago, it was demonstrated that introduction of 
double strand RNA (dsRNA) into eukaryote cells triggered a 
sequence-specific gene silencing (Fire A, 1998). The dsRNA 
is processed by pre-existing intracellular machinery, along a 
pathway that forms the interfering RNA which mediates mRNA 
degradation. Briefly, in the cytosol, the dsRNA is cleaved by 
DICER endoribonuclease into small fragments of 21-23 nt, called 
siRNA. These recruit Argonaute-2 and other proteins forming 
the RISC complex (RNA-induced silencing complex). Within 
the complex, RNA strands are separated, being one of them 
a template to find an mRNA with a complementary sequence 
(Tang, 2005). Once the matching mRNA is found, Argonaute-2 
cleaves it (Grimm, 2009) and prevents its translation (Figure 1). 
Detailed description of the mechanism of functioning of these 
RNA molecules can be found in the works of Ipsaro and Joshua-
Tor (Ipsaro and Joshua-Tor, 2015) and Kobayashi and Tomari 
(Kobayashi and Tomari, 2016).
RNAi technique offers several advantages to modulate gene 
expression in whole animals compared to the widely used 
knockout models, to decrease protein function. Working 
with siRNAs is simpler and cheaper than generation and 
maintenance of knockout models, albeit some genes cannot be 
knocked-out. Despite these advantages, RNA silencing involves 
certain general challenges, as efficient siRNA delivery into the 
target cell, enough expression levels within the cell and cell 
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specificity. The latter is important to avoid siRNA expression 
into other organs, and even more important when the objective 
is to target a specific cell within a desired organ (Whitehead et 
al, 2009). Finally, the intervention to express the siRNA must 
be safe, avoiding collateral alterations within the cell or in the 
surrounding tissue induced by immune response.
Exogenous siRNA could be express in vivo using different 
strategies. The most direct way is infusing synthetic siRNA, 
conjugated with particles that stabilize its structure, preventing 
early degradation in the tissue (Chira et al, 2015, Jasinski et 
al, 2017). siRNA could be stabilized by conjugation with 
cholesterol or with different kind of nanoparticles as aptamers, 
micelles, liposomes, cationic polymers. This is a factor to 
consider not only for a systemic but local administration of 
siRNA, since will improve the rate of cellular uptake, prevent 
immune system activation, avoid renal elimination, and confers 
pH and thermal stability, enhancing siRNA delivery efficiency 
(Tatiparti et al, 2017).
Other options consider to generate a short hairpin RNA 
(shRNA), introduced in the cells with viral vectors. shRNA is 
synthesized from a DNA cassette consisting of two sections 
of complementary sequences joined by a loop sequence. This 
cassette is transcribed by RNA polymerase III from the host 
cell, and its expression is dependent on a promoter like U6, H1 
or 7SK (Figure 2). The hairpin structure is recognized by the 
enzyme DICER, which cleaves it generating a siRNA duplex 
(McIntyre and Fanning, 2006). The following sections of this 
review will focus on cardiac delivery of siRNA and a brief 
discussion of lentiviral vectors to express shRNA in vivo in the 
heart, during pathophysiological processes.
CARDIAC siRNA DELIVERY
Transient siRNA expression
Cardiomyocytes are approximately 75% of the heart’s volume, 
but less than 60% of the total cells in the heart. Other cell 
types like fibroblasts and vessel cells constitute anatomic 
barriers that prevent proper siRNA delivery. Furthermore, non-
myocyte cells could be also potential targets to compete with 
cardiomyocytes for siRNA transfection or vector transduction. 
The correct choice of a siRNA delivery route to the heart is a 
key issue to consider to a successful cardiomyocyte expression. 
If the intention is a silencing effect restricted to the heart, 
intravenous delivery of naked siRNA is certainly not an option, 
since it would be distributed throughout the organism. Several 
studies have shown that intraperitoneal injection, subcutaneous 
delivery through pumps or direct infusion by the blood stream 
of siRNA molecules not only had effects on the heart but also 
affect other organs such as lung and kidney (Arnold et al, 2007, 
Clemente et al, 2007, Wang et al, 2009). This inconvenience 
could be avoided by directly injecting the siRNA in vivo into the 
myocardial wall. We found that direct intramyocardial injection 
of naked siRNA in the left ventricle to silence the membrane 
Na+/H+ exchanger (NHE1) produced a reduction of cardiac 
protein expression without affecting other organs (Morgan et al, 
2011). Similarly, other authors found that this delivery strategy 
to target other cardiac proteins such as epidermal growth factor 
receptor (EGFR) (Feng et al, 2012) and thyrotropin releasing 
hormone (TRH) (Schuman et al, 2011) led to protein expression 
reduction with functional consequences.
It is important to highlight that naked siRNA without any 
stabilizing modification is rapidly degraded outside the cell, 
in the tissue. With this strategy, the silencing effect is greater 
between 48-72 hours, achieving an expression reduction 
of approximately 55-70% (Morgan et al, 2011, Feng et al, 
2012). The broad silencing of protein expression along the left 
ventricle could result from the diffusion of siRNA molecules 
from the injection site in the apex along the myocardium. Also 
it could be possible that siRNA molecules travel from one cell to 
another through gap junctions containing connexin 43 (Kizana 
et al, 2009). The low stability of naked siRNA and the specific 
protein turnover rate, determines that the effect vanishes 
around a week later. Therefore, a potential chronic treatment 
would need periodical repeat of the procedure, although the 
reversibility of the effect could be considered as an advantage 
for temporary inhibition. siRNA conjugation with different kind 
of nanoparticles, although widely used in cancer research and 
as a potential therapeutic tool was little utilized in the heart 
field. Recently, cholesterol conjugated siRNA was injected into 
the heart wall to decrease the expression of renalase (Huang et 
al, 2016). After 24 h, protein expression was ~75% decreased 
and the siRNA fluorescence tag signal detected, indicative of 
prolonged stability.
The use of siRNA in vitro showed in some cases activation of the 
Figure 1. Mechanism of RNAi. DICER enzyme recognizes long 
dsRNAs and shRNAs, and cleaves them to fragments of 21-23 nt called 
siRNAs. These recruit the RISC forming machinery, within which the 
siRNA strands separate and one is used as a template to search for 
complementary mRNA. After, Argonaute 2 protein within the RISC 
cleaves the messenger, preventing its translation.
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interferon system (Samuel-Abraham and Leonard, 2010), which 
could mask a specific response. Delivery of siRNA through the 
hydrodynamic pulse achieved a reduction of the protein without 
affecting similar proteins or inducing an inflammatory response 
in the heart (Arnold et al, 2007, Clemente et al, 2007). From the 
clinical perspective, the highly invasive nature of this procedure 
force to consider that the potential therapeutic application of the 
technique is still too far.
Long term siRNA expression
Due to the low stability of the naked siRNA, long term silencing 
could be obtained with viral vectors that transduce the target 
cell with the coding sequence of a specific shRNA. The three 
most commonly viral systems used are adenovirus (Wu et al, 
2014, Gao et al, 2017), lentivirus (Zhang et al., 2015, Brea et al, 
2016) and adeno-associated virus (Suckau et al, 2009, Miyazaki 
et al, 2012). These vectors have the advantage of possessing 
a better efficiency for siRNA delivering and with adequate 
modifications, minimize an immune response that could 
compromise a correct delivery or mask the siRNA effect through 
off-target effects (Merentie et al, 2016). Some viral vectors have 
the possibility of being intravenously injected, since though 
the vectors are distributed throughout the whole organism, the 
shRNA promoter can only be expressed in the target organ. In 
addition, the vector could also have a special tropism towards 
the heart. In other words, despite being distributed throughout 
the organism, only the heart will be transduced.
Lentivirus, which does not have cardiac tropism, could limit 
their expression to the heart by an intraventricular injection. 
Lentiviral vectors derived from human immunodeficiency virus 
type 1 (HIV-1) are capable of transducing a wide variety of 
dividing and terminals cells, where they are stably integrated 
into the host genome, allowing prolonged expression of the 
transgene. The general strategy used to produce a recombinant 
lentiviral vector has been to eliminate elements of the virus 
genome limiting its replication and pathogenicity. This is 
crucial to avoid possible recombination and immune response 
(Tiscornia et al, 2003).
Third generation lentiviral vectors used by us were generated 
with four plasmids (Figure 2). The transfer vector contains the 
transgene of interest, and all cis-elements required for RNA 
production and packaging. The packaging system involves three 
additional plasmids, which provide the required trans-factors, 
called Gag-Pol, envelope protein and Rev, respectively. Gag-Pol 
encodes for an integrase, a reverse transcriptase, and structural 
proteins. Structural proteins are required for particle production, 
whereas integrase and reverse transcriptase are packaged within 
the viral particle, becoming active during the process of infection 
and integration. Rev interacts with the response element Rev 
(RRE), which is a sequence contained in the transfer vector that 
increases the export of viral genomic RNA from the nucleus, 
favoring the increase of the viral titer (Tiscornia et al, 2003). 
Vesicular Stomatitis Virus G-protein (VSV-G) incorporated in 
the envelope of the viral particles confer them the ability to 
transduce a variety of cell types (Figure 2).
STUDYING SLOW FORCE RESPONSE BY GENE 
SILENCING
Hemodynamic increase induce a cardiac output adaptation that 
activates intracellular pathways, that if chronically sustained 
lead to pathological consequences as cardiac hypertrophy 
(CH) and heart failure. Acute myocardial stretch, originates 
an initial rise in contractility, followed by a slowly continuous 
force increase. This slow force response (SFR) is originated 
by a stretch-triggered activation of Angiotensin II receptor 
1a (AT1R), as in CH. A proposed signaling pathway for the 
SFR includes a sequence of: 1) Stretch-triggered release of 
Angiotensin II/AT1-R activation, 2) Release/formation of 
endothelin, 3) activation of the mineralocorticoid receptor 
(MR), 4) transactivation of EGFR, 5) increased formation of 
mitochondrial reactive oxygen species (ROS), 6) activation 
of redox-sensitive kinases, 7) NHE1 activation, 8) increase in 
intracellular Na+ concentration, and 9) increase in Ca2+ transient 
Figure 2. Delivery of shRNA by lentiviral vectors. A. Scheme of the transfer and packaging vectors used to produce the third generation lentivirus. 
B. HEK 293T cells are transfected with the 4 plasmids, and produce viral particles which are then used to inject the heart. The virus enters into the 
cardiomyocytes and allows the expression of shRNA in the nucleus, triggering the silencing machinery.
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amplitude through the Na+/Ca2+ exchanger (Figure 3A). 
Experimental evidence indicates that a good option to treat CH 
and heart failure would be preventing NHE1 or MR activation 
(Pitt et al, 2001, Zannad et al, 2011, Karmazyn, 2013), two 
proteins that in addition to EGFR were target for gene silencing. 
Following we discuss results of siRNA use against NHE1, MR 
and EGFR.
The NHE1 is an integral protein of the cardiomyocyte plasma 
membrane that removes H+ from the cytosol in exchange for 
Na+. Hyperactivity of cardiac NHE1 induces SFR, CH and heart 
failure. Pharmacological inhibition of NHE1 has been shown to 
be beneficial in animal models of cardiac pathologies. However, 
clinical trials with NHE1 inhibitors failed to yield positive results 
or worst were associated to undesired side effects probably due 
to a tissue unspecific NHE1 inhibition.
Direct injection of naked siRNA into the mouse heart wall, 
temporarily decreases NHE1 expression, producing functional 
silencing (Figure 3B and 3C) (Morgan et al, 2011). NHE1 
dependent proton efflux after an acute acidic challenge 
was minimized. Protein expression reduction was not even 
throughout the entire myocardium, rather, it gets reduced 
from the injection site. Expression in liver, lung or brain was 
not changed, indicating that the silencing was limited to the 
injected organ. For a long-term silencing, the same siRNA 
sequence was incorporated into a third-generation lentivirus. A 
lentivirus carrying a shRNA-NHE1 and a reporter protein was 
injected at two sites in the free wall of rat heart left ventricle 
(Perez et al, 2011). A month later, red fluorescence staining of 
the reporter protein was observed by confocal microscopy in 
both the apex and base of the heart, as well as in the papillary 
muscles, where ex vivo, the SFR was studied (Figure 4A). A 
significant reduction of NHE1 protein expression together with 
cancellation of the SFR was observed (Figure 4B). The same 
combination of lentivirus and intramyocardial injection was 
used to verify the effect of NHE1 silencing in the hypertrophic 
myocardium of SHR rats. Long term NHE1 silencing affected 
~50% of the protein expression, reversing the pathologic CH 
and producing a significant reduction in cardiac parietal stress 
(Nolly et al, 2015). As with naked siRNA, the silencing effect 
was specific to the heart, since NHE1 expression was not 
modified in lung or liver.
Mineralocorticoid receptor (MR) is overexpressed in the failing 
heart where the clinical efficacy of MR inhibitors is well 
established (Pitt et al, 1999, Pitt et al, 2001, Zannad et al, 2011). 
However, the exact mechanisms by which MR antagonists 
provide cardiovascular protection in patients with heart failure 
are not completely understood. Its participation in SFR had 
been demonstrated using the inhibitors spironolactone and 
eplerenone (Caldiz et al, 2011). Since those are non-selective 
compounds and have been described as inverse agonist of the 
MR, siRNA was used as a specific inhibitory strategy. shRNA-
MR incorporated into a lentivirus was injected into the left 
ventricle wall, reducing MR expression at both cardiac wall and 
papillary muscle (Figure 4C). The functional consequence of 
MR silencing was the cancellation of the SFR (Figure 4C) (Diaz 
et al, 2013). Alternatively, lentiviruses expressing shRNA-MR 
were injected into mice oocytes to generate inducible MR 
knock-down animals, allowing shRNA temporary expression 
control (Montes-Cobos et al, 2015). shRNA was expressed in 
all tissues analyzed and produced after 15 days, at least in heart 
and kidney a ~50% MR reduction, preventing CH.
EGFR belongs to a tyrosine kinase family involved in numerous 
biological processes. It was extensively studied in cancer, 
diabetes and cardiovascular diseases (Hervent and De Keulenaer, 
2012, Forrester et al, 2016). Different siRNA delivery strategies 
were used to specifically silence this receptor in the heart. In our 
hands, lentivirus expressing shRNA-EGFR was injected in the 
cardiac left ventricle wall of rats  (Brea et al, 2016). Expression 
of EGFR decreased by 60%, without affecting other family 
member receptors like ErbB2 or ErbB4 (Figure 4D). As for 
NHE1 or MR silencing, reduced protein expression correlated 
with a minimized SFR in papillary muscles expressing shRNA-
EGFR (Figure 4D). Other authors have shown that siRNA 
duplex injected directly into the cardiac wall produces 45% 
decrease of EGFR expression after 48 hours (Feng et al, 2012). 
The functional consequence was a reduction of the incidence of 
ventricular fibrillation induced after reperfusion. Nevertheless, 
Figure 3. Naked siRNA in the heart. A. Scheme of the proposed 
mechanism leading to the SFR. B. Silencing of NHE1 in the mouse 
heart. Mice were injected once in the wall of the left ventricle with 20 
μg of naked siRNA NHE1 or siRNASCR. Left panel: immunoblots 
of heart lysates. Right panel: bar graph shows average expression of 
protein. C. Transport activity of NHE1 in papillary muscle. Papillary 
muscles were perfused with a bicarbonate-free (HEPES)-buffered 
medium. Left panel: representative experiments recording intracellular 
pH (pHi) corresponding to papillary muscles treated with siRNA 
NHE1, siRNA SCR and control without siRNA. Right panel: summary 
of the effects of the siRNA treatments on NHE1 exchange activity. *P 
<0.05. [B-C: adapted from (Morgan et al.  2011)].
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there is no evaluation of silencing of other family receptors or 
of EGFR in other organs.
CONCLUSION
The RNAi technique allows studying a protein function 
specifically localized in the heart. Different strategies have 
been used to express siRNA in cardiomyocytes including 
administration of naked RNA duplexes or conjugated to 
nanoparticles to improve stability, safety and cellular uptake. 
Viral vectors such as adenoviruses, adeno-associated viruses 
and lentiviruses have effectively been used to inhibit long-term 
protein expression and study its functional consequences. The 
gene silencing results obtained in animals are encouraging to 
consider it as an alternative therapeutic tool. The scarce clinical 
trials with interference RNA are directed to treat different 
pathologies that do not include the heart as target organ. Heart 
access presents serious difficulties to obtain an efficient and 
specific silencing minimizing a potential immune response. 
Intramyocardial injection presented here with small animals, 
although highly invasive, may probably be considered as an 
option during a simple catheterism intervention in higher 
animals.
Figure 4. Lentivirus in the heart. A. Upper panel: scheme of a cardiomyocyte showing the proteins that our group has silenced by lentivirus. Bottom 
panel: representative confocal images (4X) of myocardial slices from hearts injected with lentiviral vectors, as well as from a sham-operated rat. 
B. Upper panel: western blot and the averaged results of hearts injected with lentivirus l-shNHE1 and l-shSCR. Bottom panel: averaged SFR 
expressed as percentage of the initial rapid phase from both groups of animals. C. Upper panel: western blot and the averaged results of hearts 
injected with lentivirus l-shMR and l-shSCR. Bottom panel: averaged SFR expressed as percentage of the initial rapid phase from both groups of 
animals. D. Upper panel: western blot and the averaged results of hearts injected with lentivirus l-shEGFR and l-shSCR. Bottom panel: averaged 
SFR expressed as percentage of the initial rapid phase from both groups of animals. [B: adapted from (Perez et al.  2011), C: adapted from (Diaz 
et al, 2013), D: adapted from (Brea et al. 2016)].
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